Research ID |
Investigator Name |
Research Topic |
Research Status |
16 | Montira | Does ketosteril slow CKD progression? | Drafting MS |
17 | Atiporn | CKD mineral and bone disorder (MBD): progression | Suspend |
18 | Montira | ESA in anemia: risk and benefit (Hb level, CVD, stroke/thrombosis) | Drafting MS |
19 | Montira | Prevalence and association factors of polypharmacy burden in CKD and dialysis patients. | Suspend |
20 | Sarinya | The effect of SGLT2 to ESRD stage in CKD patient | Drafting MS |
29 | Sukanya | Factors Affecting Quality of Life in Patients Undergoing Percutaneous Coronary Intervention in Thailand: Thai PCI registry | Published |
39 | Tanawan | Economic evaluation of add-on SGLT2 inhibitors and GLP-1 receptors agonist in type 2 diabetes with established cardiovascular disease and/or diabetes kidney disease in Thailand | Approved |
50 | Kamolpat | Clinical effectiveness of phosphate binders for treating hyperphosphatemia in end-stage renal disease patients: a multicenter real-world study | Published |
54 | Romen | CKD disease progression: A multi-state analysis by conventional statistical and machine learning models | On going |
55 | Ammarin | Deprodustat vs darbepoetin alfa on Hb level in dialysis patients | Suspend |
62 | Amarit | Machine-learning counterfactual approach of SGLT2i effect on CKD outcome | Analysis |
138 | Sinee | Bone Mineral Density in CKD stages 3-4 patients | Approved |